Eli Lilly and Company (LLY)
| Market Cap | 814.86B |
| Revenue (ttm) | 38.92B |
| Net Income (ttm) | 7.34B |
| Shares Out | 900.43M |
| EPS (ttm) | 8.12 |
| PE Ratio | 111.43 |
| Forward PE | 43.66 |
| Dividend | $5.20 (0.57%) |
| Ex-Dividend Date | Aug 15, 2024 |
| Volume | 1,435,953 |
| Open | 906.31 |
| Previous Close | 906.18 |
| Day's Range | 903.46 - 915.50 |
| 52-Week Range | 516.57 - 972.53 |
| Beta | 0.42 |
| Analysts | Strong Buy |
| Price Target | 941.67 (+4.06%) |
| Earnings Date | Oct 31, 2024 |
About LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the... [Read more]
Financial Performance
In 2023, Eli Lilly's revenue was $34.12 billion, an increase of 19.56% compared to the previous year's $28.54 billion. Earnings were $5.24 billion, a decrease of -16.08%.
Financial StatementsAnalyst Forecast
According to 22 analysts, the average rating for LLY stock is "Strong Buy." The 12-month stock price forecast is $941.67, which is an increase of 4.06% from the latest price.
News
Axcelead DDP and Lilly Enter into Research and Collaboration Agreement
TOKYO--(BUSINESS WIRE)-- #DrugDiscovery--Axcelead DDP and Lilly Enter into Research and Collaboration Agreement.
Radioactive cancer technology: New billion dollar opportunity?
CNBC's Angelica Peebles joins 'Squawk Box' with the latest news.
World's Biggest Hedge Fund Sells Apple, Eli Lilly Stock, and Buys Microsoft, Moderna
Bridgewater Associates slashed a stake in Apple, halved its Lilly investment, doubled down on Microsoft, and bought Moderna in the second quarter.
US FDA approves Eli Lilly's eczema drug
Eli Lilly said on Friday the U.S. Food and Drug Administration approved its eczema drug for use in adults and children above 12 years old.
FDA Approves Lilly's EBGLYSS™ (lebrikizumab-lbkz) for Adults and Children 12 Years and Older with Moderate-to-Severe Atopic Dermatitis
EBGLYSS provides a new first-line biologic treatment for moderate-to-severe atopic dermatitis that is not well controlled with topicals Patients treated with EBGLYSS experienced significant skin clear...
Calls of the Day: Vistra, Garmin, Tesla and Eli Lilly
The Investment Committee discuss the latest Calls Of The Day.
Citi resumes coverage of Eli Lily with a Buy rating: Should you invest?
Citi has resumed coverage of Eli Lilly & Co. (NYSE: LLY) with a “Buy” rating, setting a price target of $1,060 per share—implying a potential 13% upside from the current stock price.
Eli Lilly Invests $1.8B To Expand Drug Output in Ireland
Eli Lilly (LLY) said Thursday it will spend $1.8 billion to expand production in Ireland of its popular diabetes and weight-loss drugs, as well as some active ingredients used in its Alzheimer's treat...
Healthcare Stocks Have Popped. Consider These 2 That Haven't.
Money has poured into the sector as markets have grown concerned about the economy.
Roche Setback Is Big for Eli Lilly, Novo Nordisk as Obesity Drug Battle Ramps Up
The company's stock was falling after a report detailing side effects from its once-daily weight-loss pill.
Eli Lilly invests $1.8 bln in Ireland sites to scale up Alzheimer's, obesity drug production
Eli Lilly is investing $1.8 billion across two manufacturing sites in Ireland to boost production of its hugely popular obesity drug and a newly approved treatment for Alzheimer's, the drugmaker said ...
Eli Lilly to invest $1.8 billion to expand manufacturing for weight loss, diabetes and Alzheimer's drugs
Eli Lilly will invest $1.8 billion to boost manufacturing for its newly approved Alzheimer's drug and highly popular weight loss and diabetes treatments, among other medicines, in Ireland. The pharma...
Lilly expands manufacturing footprint in Ireland with $1.8 billion investment
Company ups manufacturing investment in Limerick by $1 billion; unveils new $800 million Kinsale facility New investment will enhance global medicine production, benefiting millions of patients worldw...
Health Rounds: Once-weekly insulin from Eli Lilly appears effective as daily injections
Eli Lilly's experimental insulin that is injected just once a week is as effective as daily insulin injections for maintaining blood sugar levels in patients with type 1 or type 2 diabetes, researcher...
With once-a-week dosing, insulin efsitora alfa delivers similar A1C reduction compared to daily insulin in adults with type 1 diabetes
Detailed results were published in The Lancet and simultaneously presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2024 INDIANAPOLIS , Sept. 10, 2024 /PRNewswire/ -...
Once-weekly dose of insulin efsitora alfa delivers A1C reduction consistent with the most advanced daily insulin in people with type 2 diabetes
In QWINT-2, efsitora helped adults naïve to insulin therapy currently using and not using GLP-1 receptor agonists achieve an A1C below 7% Detailed results were published in The New England Journal of...
Lilly appoints insider as finance chief amid rising investments to boost capacity
U.S. drugmaker Eli Lilly on Monday said it has appointed insider Lucas Montarce as its new chief financial officer, effective immediately, months after former CFO Anat Ashkenazi stepped down to join G...
Calls of the Day: Eli Lilly and Netflix
The Investment Committee debates how to trade these names: Netflix and Eli Lilly.
The Highly Anticipated FDA Approvals of Galderma's Nemolizumab and Eli Lilly's Lebrikizumab are Expected to Shift Dermatologists' Perceptions of the Atopic Dermatitis Market
While reported use of Sanofi/Regeneron's Dupixent has declined with the adoption of LEO's Adbry, Pfizer's Cibinqo, and AbbVie's Rinvoq, the overall population receiving advanced treatments is on the r...
Lilly appoints Lucas Montarce as executive vice president and chief financial officer
INDIANAPOLIS , Sept. 9, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the appointment of Lucas Montarce as executive vice president and chief financial officer (CFO) and membe...
The Big 3: LLY, XOM & PLTR
Joe Tigay joins Ben Lichtenstein and Nicole Petallides to break down the technical trends in Eli Lilly (LLY), Exxon Mobil (XOM), and Palantir (PLTR). ======== Schwab Network ======== Empowering every ...
Stock Of The Day: Here's Why Weight-Loss Drug Maker Eli Lilly Has Reversed
When stocks rally, they tend to run into resistance if they reach a price level that had been resistance before. And sometimes, after hitting it they reverse and head lower.
Health Rounds: Next generation Lilly weight-loss drug shows added heart, liver benefits
Eli Lilly's experimental next generation weight-loss drug mimics three hormones instead of just one or two and continues to show promising clinical trial results for additional health benefits, the co...
Healthy Returns: Eli Lilly could soon become the first $1 trillion health-care stock
Eli Lilly could be on its way to topping $1 trillion in market value. Meanwhile, Abbott launches its first over-the-counter continuous glucose monitor in U.S.
Eli Lilly and Company (LLY) Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)
Eli Lilly and Company (NYSE:LLY) Morgan Stanley 22nd Annual Global Healthcare Conference Call September 5, 2024 7:45 AM ET Company Participants Jacob Van Naarden - Executive Vice President & Presiden...